Burkitt lymphoma (BL) is an aggressive mature B-cell neoplasm. The cytogenetic hallmark are MYC-involving translocations, most frequently as t(8;14)(q24;q32). Additional cytogenetic abnormalities are seen in the majority of cases. The most frequent additional aberration involves the long arm of chromosome 1, either as partial or complete trisomy 1q. A very rare additional aberration is a supernumerary isochromosome 1q, i(1)(q10), resulting in tetrasomy 1q. The biological significance of this aberration is unclear. We present a highly aggressive case of BL in a child with immature B-cell immunophenotype (IP) and supernumerary i(1)(q10). Diagnostic karyotyping showed 47,XY,+i(1)(q10),t(8;14)(q24;q32)[2]/47,idem,del(15)(q24)[21]/46,XY[2]. aCGH analysis detected a gain of 1p12qter and a loss of 15q22q25. FISH analysis confirmed the isodicentric chromosome 1, which has not previously been reported in BL. In the literature, supernumerary i(1)(q10) was found in 11 cases of which >80% presented with immature B-cell IP and >60% relapsed or died. Tetrasomy 1q resulting from supernumerary idic(1)(p12) or i(1)(q10) is a rare genetic event in BL and probably associated with immature B-cell IP. We propose that high amplification of genes on chromosome 1p12qter may contribute to the BL IP and disease progression.

Keywords:
Burkitt lymphoma, Isochromosome, Isodicentric chromosome 1, Tetrasomy 1q
1.
Bacher U, Haferlach T, Alpermann T, Kern W, Schnittger S, Haferlach C: Several lymphoma-specific genetic events in parallel can be found in mature B-cell neoplasms. Genes Chromosomes Cancer 50:43-50 (2011).
2.
Barbouti A, Stankiewicz P, Nusbaum C, Cuomo C, Cook A, et al: The breakpoint region of the most common isochromosome, i(17q), in human neoplasia is characterized by a complex genomic architecture with large, palindromic, low-copy repeats. Am J Hum Genet 74:1-10 (2004).
3.
Barki-Celli L, Lefebvre C, Le Baccon P, Nadeau G, Bonnefoix T, et al: Differences in nuclear positioning of 1q12 pericentric heterochromatin in normal and tumor B lymphocytes with 1q rearrangements. Genes Chromosomes Cancer 43:339-349 (2005).
4.
Bellan C, Stefano L, Giulia de F, Rogena EA, Lorenzo L: Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach. Hematol Oncol 28:53-56 (2010).
5.
Bernheim A, Berger R: Cytogenetic studies of Burkitt lymphoma-leukemia in patients with acquired immunodeficiency syndrome. Cancer Genet Cytogenet 32:67-74 (1988).
6.
Bessenyei B, Ujfalusi A, Balogh E, Olah E, Szegedi I, Kiss C: Jumping translocation of chromosome 1q associated with good clinical outcome in a case of Burkitt leukemia. Cancer Genet 204:207-210 (2011).
7.
Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, et al: Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 98:7319-7324 (2001).
8.
Busson-Le Coniat M, Salomon-Nguyen F, Dastugue N, Maarek O, Lafage-Pochitaloff M, et al: Fluorescence in situ hybridization analysis of chromosome 1 abnormalities in hematopoietic disorders: rearrangements of DNA satellite II and new recurrent translocations. Leukemia 13:1975-1981 (1999).
9.
Capello D, Scandurra M, Poretti G, Rancoita PM, Mian M, et al: Genome wide DNA-profiling of HIV-related B-cell lymphomas. Br J Haematol 148:245-255 (2010).
10.
Craig FE, Foon KA: Flow cytometric immunophenotyping for hematologic neoplasms. Blood 111:3941-3967 (2008).
11.
D'Achille P, Seymour JF, Campbell LJ: Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. Cancer Genet Cytogenet 171:52-56 (2006).
12.
Davidsson J, Andersson A, Paulsson K, Heidenblad M, Isaksson M, et al: Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3. Hum Mol Genet 16:2215-2225 (2007).
13.
de la Roche M, Worm J, Bienz M: The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells. BMC Cancer 8:199 (2008).
14.
Garcia JL, Hernandez JM, Gutierrez NC, Flores T, Gonzalez D, et al: Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia 17:2016-2024 (2003).
15.
Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE: New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 4:1131-1133 (2005).
16.
ISCN (2013): An International System for Human Cytogenetic Nomenclature, Shaffer LG, McGowan-Jordan J, Schmid M (eds) (S. Karger, Basel 2013).
17.
Itoyama T, Nanjungud G, Chen W, Dyomin VG, Teruya-Feldstein J, et al: Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer 35:318-328 (2002).
18.
Kim JE, Woo KS, Kim KE, Kim SH, Park JI, et al: Duplications of the long arm of both chromosome 1, dup(1)(q21q32), leading to tetrasomy 1q in myelodysplastic syndrome. Leuk Res 34:e210-e212 (2010).
19.
Kjeldsen E, Tordrup D, Hubner GM, Knudsen BR, Andersen FF: Topoisomerase I deficiency results in chromosomal alterations in cervical cancer cells. Anticancer Res 30:3257-3265 (2010).
20.
Komrokji R, Lancet J, Felgar R, Wang N, Bennett JM: Burkitt's leukemia with precursor B-cell immunophenotype and atypical morphology (atypical Burkitt's leukemia/lymphoma): case report and review of literature. Leuk Res 27:561-566 (2003).
21.
Lai JL, Fenaux P, Zandecki M, Nelken B, Huart JJ, Deminatti M: Cytogenetic studies in 30 patients with Burkitt's lymphoma or L3 acute lymphoblastic leukemia with special reference to additional chromosome abnormalities. Ann Genet 32:26-32 (1989).
22.
Le Baccon P, Leroux D, Dascalescu C, Duley S, Marais D, et al: Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Genes Chromosomes Cancer 32:250-264 (2001).
23.
Lones MA, Sanger WG, Le Beau MM, Heerema NA, Sposto R, et al: Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from children's cancer group study CCG-E08. J Pediatr Hematol Oncol 26:169-178 (2004).
24.
Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, et al: BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 69:7577-7586 (2009).
25.
Meyer LR, Zweig AS, Hinrichs AS, Karolchik D, Kuhn RM, et al: The UCSC genome browser database: extensions and updates 2013. Nucleic Acids Res 41:D64-D69 (2013).
26.
Miles RR, Arnold S, Cairo MS: Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol 156:730-743 (2012).
27.
Mitelman F, Johansson B, Mertens FE: Mitelman database of chromosome aberrations and gene fusions in cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman (2012). Last accessed February 2013.
28.
Navid F, Mosijczuk AD, Head DR, Borowitz MJ, Carroll AJ, et al: Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: The Pediatric Oncology Group experience. Leukemia 13:135-141 (1999).
29.
Onciu M, Schlette E, Zhou Y, Raimondi SC, Giles FJ, et al: Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma. Cancer 107:1084-1092 (2006).
30.
Poirel HA, Cairo MS, Heerema NA, Swansbury J, Auperin A, et al: Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Leukemia 23:323-331 (2009).
31.
Pui CH, Carroll AJ, Raimondi SC, Schell MJ, Head DR, et al: Isochromosomes in childhood acute lymphoblastic leukemia: a collaborative study of 83 cases. Blood 79:2384-2391 (1992).
32.
Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, et al: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 94:3294-3306 (1999).
33.
Scholtysik R, Kreuz M, Klapper W, Burkhardt B, Feller AC, et al: Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis. Haematologica 95:2047-2055 (2010).
34.
Seghezzi L, Addis P, Giglio S, Invernizzi R, Maserati E: Jumping translocations in acute lymphoblastic leukemia. Cancer Genet Cytogenet 80:80-81 (1995).
35.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, ed 4 (IARC, Lyon 2008).
36.
Toujani S, Dessen P, Ithzar N, Danglot G, Richon C, et al: High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma. PloS One 4:e7089 (2009).
37.
Wasterlid T, Jonsson B, Hagberg H, Jerkeman M: Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish lymphoma registry study. Leuk Lymphoma 52:2090-2096 (2011).
38.
Wenzel SS, Grau M, Mavis C, Hailfinger S, Wolf A, et al: MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia 27:1381-1390 (2013).
39.
Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, et al: Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 91:1873-1881 (1998).
40.
Wodzinski MA, Watmore AE, Lilleyman JS, Potter AM: Chromosomes in childhood acute lymphoblastic leukaemia: karyotypic patterns in disease subtypes. J Clin Pathol 44:48-51 (1991).
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.